BLAINTRAVENOUSSOLUTION
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
MYXREDLIN (insulin human) by Baxter is insulin, including myxredlin is the regulation of glucose metabolism. First approved in 2019.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYXREDLIN is an intravenous insulin human solution approved in 2019 for acute care settings. It regulates glucose metabolism by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. The drug is used in hospitalized patients requiring rapid insulin delivery and tight glycemic control.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30), suggesting stable but not rapidly expanding team opportunities.
Mechanism of Action
insulin, including MYXREDLIN is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein…
Pharmacologic Class:
Insulin
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
Started Jan 2011
13 enrolled
DiabetesDiabetes Mellitus, Type 1
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics
Started Aug 2008
28 enrolled
Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.
Started Jul 2008
42 enrolled
Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.
Started Jan 2008
25 enrolled
Diabetes Mellitus
Worked on MYXREDLIN at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.